News
-
Tirzepatide Pyridoxine: What Vitamin B6 Adds
Tirzepatide/pyridoxine is a compounded combination of tirzepatide and vitamin B6. The B6 is usually included with nausea in mind, but no clinical trial has shown that the combination works better than tirzepatide alone.
-
DSIP Side Effects: What Human Studies Found
Reported DSIP side effects include sleep pressure, headache, nausea, vertigo, sweating and occasional blood-pressure changes, but small, short studies leave long-term risk largely unknown.
-
How Long Does BPC-157 Take to Work?
No human trial establishes a reliable BPC-157 onset. Animal studies measured changes from day 1 through several weeks, but a prescribed course is judged by the specific outcome and follow-up—not a promised start day.
-
Peptides vs Steroids: What Makes Them Different?
Peptides and anabolic steroids are different molecules with different targets, evidence, risks, and legal status. A peptide is not simply a steroid under a newer name.
-
PT-141 for Men: What the Male Studies Show
PT-141 produced measurable erectile responses in early male trials, including studies involving men who reported an inadequate response to sildenafil. The evidence is limited, route-specific, and not the same as an established male indication.
-
Semaglutide Before Surgery: Do You Need to Stop?
Most patients can continue semaglutide before an elective procedure, but the plan changes when delayed stomach emptying is more likely. The anesthesia and prescribing teams should make that call together.
-
Semaglutide Drug Interactions: What Matters
Most semaglutide interactions are not classic liver-enzyme conflicts. The practical concerns are low blood sugar with insulin or sulfonylureas and altered absorption of oral medicines that need tightly controlled exposure.
-
Semaglutide Sulfur Burps: Why They Happen
Sulfur-smelling burps are a real but poorly measured digestive complaint with semaglutide. Trials counted belching, not its smell, and the likely explanation combines slower digestion with hydrogen-sulfide gas.
-
Tesamorelin for Belly Fat: What the Studies Show
Tesamorelin has reduced visceral abdominal fat in randomized trials, most convincingly in adults with HIV-associated lipodystrophy. That evidence does not make it a general weight-loss drug or a reliable way to shrink the fat just under the skin.
-
Tirzepatide for PCOS: What the Evidence Shows
Early studies connect tirzepatide with weight and metabolic changes in people with PCOS, but the direct evidence is still small. Pregnancy plans and the reason for prescribing matter as much as the diagnosis.
-
Tirzepatide Plateau: Why Weight Loss Slows
A tirzepatide plateau is usually the point where a smaller body and stronger biological pressure to maintain weight balance the medication's effects. A brief stall is not the same thing, and a prescriber should review the pattern before changing treatment.
-
BPC-157 for Inflammation: What the Evidence Shows
Rodent studies report smaller gut lesions, lower oxidative-stress measures and altered inflammatory signaling. No human trial has shown that BPC-157 lowers inflammation.
-
Is Semaglutide FDA Approved? Not When Compounded
Promise dispenses semaglutide as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. Ozempic, Rybelsus and Wegovy have approvals for specific uses.
-
KLOW vs GLOW: What KPV Adds to the Blend
KLOW and GLOW share BPC-157, TB-500, and GHK-Cu; KLOW adds KPV, an inflammation-focused tripeptide backed by cell and mouse studies—not blend-level human trials.
-
NAD Injection Dosage: What Human Studies Used
There is no validated subcutaneous or intramuscular NAD+ schedule. The best-known IV pharmacokinetic study used 750 mg over six hours, so a prescriber must set route, concentration, amount and frequency together.
-
Peptides for Joint Pain: What the Evidence Shows
Peptides for joint pain are being studied, but the evidence is mostly cell and animal work. One uncontrolled 16-person knee follow-up is not enough to show that BPC-157, TB-500 or their combination repairs human joints.
-
Semaglutide and Pregnancy: What the Evidence Says
Semaglutide is not recommended for routine weight management during pregnancy. The label calls for a two-month gap before planned conception, while early human exposure data remain limited rather than conclusive.
-
Tesamorelin vs Ipamorelin: What Sets Them Apart
Both peptides signal the pituitary to release growth hormone, but they use different receptors and carry very different levels of human evidence. Tesamorelin has phase 3 trial data; ipamorelin does not.
-
Tirzepatide and Birth Control: The 4-Week Rule
Tirzepatide may reduce the absorption of birth control taken by mouth. The current U.S. labels advise non-oral contraception or an added barrier method for four weeks after starting and after every dose increase.
-
Tirzepatide Benefits: What the Trials Show
Tirzepatide benefits are best established for weight reduction and blood-sugar control, with a branded indication for moderate-to-severe sleep apnea in adults with obesity. Heart failure, liver, blood-pressure and lipid findings are promising but narrower.
Page 11 of 18 · 344 articles